
Gennova has developed an Omicron specific vaccine GEMCOVAC-OM which has been assessed for its safety and immunogenicity when administered as a booster in participants who have received two doses of Covishield and Covaxin, the two main Covid-19 vaccines used in the immunisation drive.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5hlg4qo
via
IFTTT
0 comments:
Post a Comment